FISH in triple-negative breast cancer: a possible strategy for the future? - Wikidata - awgldk - TriplyDB

FISH in triple-negative breast cancer: a possible strategy for the future?

FISH in triple-negative breast cancer: a possible strategy for the future?

http://www.wikidata.org/entity/Q48550447

about

FISH in triple-negative breast cancer: a possible strategy for the future?

http://www.wikidata.org/entity/Q48550447

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

FISH in triple-negative breast cancer: a possible strategy for the future?

@en

FISH in triple-negative breast cancer: a possible strategy for the future?

@nl

type

label

FISH in triple-negative breast cancer: a possible strategy for the future?

@en

FISH in triple-negative breast cancer: a possible strategy for the future?

@nl

prefLabel

FISH in triple-negative breast cancer: a possible strategy for the future?

@en

FISH in triple-negative breast cancer: a possible strategy for the future?

@nl

P1433

Q48550447-437F8EAB-33EC-46DA-B522-672E40155AB9

P1476

Q48550447-25F54645-ECB2-4A3B-955B-C7B3A2F7CE00

P2093

Q48550447-0B03EE8A-AE18-4ADC-8A41-F9A047797BE9

Q48550447-0EA01F60-7AFB-40A4-8A2B-57FC39AAE862

Q48550447-2706C809-8F3F-4E0E-AA27-1B8A9DC3BE77

Q48550447-353A0F79-2966-4DB1-B52C-C420EF03B2ED

Q48550447-3A3B85A2-5939-486F-A37A-395BBE32119B

Q48550447-546D9959-DBBA-495D-A0B1-6A000D12FC69

Q48550447-56EB7653-ADEC-49B6-9C9C-7AD28209A471

Q48550447-8993AE63-F3D7-40B5-B4E2-2302F8198C5D

Q48550447-D460434B-B3F5-4C64-A8A7-07C8DE0E6DA2

P2860

Q48550447-0BB1318B-9838-4023-9900-C95AC8B85527

Q48550447-1CFDF27F-6F33-45B9-8F11-331AF20319A7

Q48550447-1FB965DE-4499-4F7D-97FD-D931110ABB16

Q48550447-20E339CC-2D08-49FF-92A9-4676912649D0

Q48550447-60819023-4422-417F-987B-3196DB5F12EE

Q48550447-689E3D6B-3D73-49F8-8E9D-FA0E33AE232E

Q48550447-8ECBDE05-B8A0-4F5E-B6CE-7809A70D5909

Q48550447-98D66034-D3F4-48D9-8830-67738EAD0153

Q48550447-D3568B37-30D6-4DC6-89AF-80C5A4D5104F

Q48550447-FC3F37E4-4F3A-40EC-AA90-64494C7769BD

P304

Q48550447-EE488641-03BD-4EF0-A3E4-640F0FD29633

P31

Q48550447-946F2C4A-0B10-4D37-9C3F-A2B1CB4BDEC0

Q48550447-aaff8d78-a8f7-4563-8318-cc77721eac0f

P356

Q48550447-40FD6FEA-6F4C-40C2-92C2-F7D736655689

P407

Q48550447-1A256E98-221D-4941-8260-C30E8D198E3A

P433

Q48550447-790DDE85-73DE-4413-BF5D-99559B045DDF

P478

Q48550447-35C1AFC3-0EF4-47A6-AFF8-B999C8F9C7B8

P577

Q48550447-7F447077-FA55-43A7-9F7B-FCE65ADB16E4

P698

Q48550447-41824101-1552-4E7C-871B-F95095CA3D6C

P356

P1433

Future Oncology

P1476

FISH in triple-negative breast cancer: a possible strategy for the future?

@en

P2093

Chiara Saggia

http://www.w3.org/2001/XMLSchema#string

Claudia Veggiani

http://www.w3.org/2001/XMLSchema#string

Elisa Rigon

http://www.w3.org/2001/XMLSchema#string

Erica Gaudino

http://www.w3.org/2001/XMLSchema#string

Oscar Alabiso

http://www.w3.org/2001/XMLSchema#string

Paola Campisi

http://www.w3.org/2001/XMLSchema#string

Renzo Luciano Boldorini

http://www.w3.org/2001/XMLSchema#string

Silvia Genestroni

http://www.w3.org/2001/XMLSchema#string

Valentina Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

Molecularly targeted therapies for metastatic triple-negative breast cancer.

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.

Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

P304

1023-1026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.15.25

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25804117

http://www.w3.org/2001/XMLSchema#string